Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital in Rome, Italy to establish a point-of-care cell therapy centre there.  Work will focus on supporting clinical trials related to therapies developed by both the hospital and Orgenesis, joint research, development of new approaches in advanced cell and gene therapies, the biotech said. READ: Orgenesis collaborates with MIDA Biotech to establish point-of-care centers at hospitals and other medical institutions across western Europe Following the implementation of the center, Orgenesis aims to then deploy its Orgenesis Mobile Processing Units and Labs (OMPULs) onsite, which serve as multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities.  "It is an honor to collaborate with the Bambino Gesù Children's Hospital, a pioneer Institution in the field of cell and gene therapies, which is developing life-changing therapies for children, our most vulnerable and deserving population," said Vered Caplan, CEO of Orgenesis. "Further to this great work, the agreement also supports the expansion of our POCare Network capacity. We remain focused on finding exceptional partners like the Bambino Gesù Children's Hospital to rapidly expand our POCare Network across Europe, North America, Asia and other regions around the world.” Professor Franco Locatelli, director of the department of pediatric hematology and oncology and cell and gene therapy, added: "Orgenesis’ new point-of-care center is being implemented to optimize promising therapies to potentially move into clinical trials and large-scale manufacturing, in a way that could substantially reduce overall costs. "Producing therapies onsite drastically streamlines manufacturing efforts and reduce time to treatment for patients. We also look forward to working closely with Orgenesis to support efforts to advance our respective cell and gene therapies." Orgenesis is bidding to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at point-of-care. Its Point of Care platform is comprised of three enabling components - therapeutics, technology and network. Contact the author at giles@proactiveinvestors.com